ADC THERAPEUTICS SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.3 USD | -5.91% |
|
-12.24% | +159.04% |
| May. 07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
| May. 06 | Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 77.71M | Sales 2025 * | 92.23M | Capitalization | 414M |
|---|---|---|---|---|---|
| Net income 2024 * | -171M | Net income 2025 * | -161M | EV / Sales 2024 * | 3.64 x |
| Net cash position 2024 * | 130M | Net cash position 2025 * | 88.83M | EV / Sales 2025 * | 3.52 x |
| P/E ratio 2024 * |
-2.33
x | P/E ratio 2025 * |
-2.73
x | Employees | 274 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on ADC Therapeutics SA
More recommendations
More press releases
More news
| 1 day | -5.91% | ||
| 1 week | -12.24% | ||
| Current month | -2.49% | ||
| 1 month | -8.70% | ||
| 3 months | -1.38% | ||
| 6 months | +814.89% | ||
| Current year | +159.04% |
1 week
4.03
5.17
1 month
4.035.17
Current year
1.456.04
1 year
0.366.04
3 years
0.3632.00
5 years
0.3656.59
10 years
0.3656.59
| Managers | Title | Age | Since |
|---|---|---|---|
Ameet Mallik
CEO | Chief Executive Officer | 51 | 22-05-08 |
Jose Carmona
DFI | Director of Finance/CFO | 51 | 22-12-18 |
Mohamed Zaki
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Hug
BRD | Director/Board Member | 65 | 19-05-31 |
Ron Squarer
CHM | Chairman | 57 | 20-03-31 |
Jean Bizzari
BRD | Director/Board Member | 69 | 22-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 4.3 | -5.91% | 1,172,160 |
| 24-05-09 | 4.57 | +3.63% | 329,931 |
| 24-05-08 | 4.41 | -8.70% | 517,405 |
| 24-05-07 | 4.83 | +8.54% | 886,012 |
| 24-05-06 | 4.45 | -9.18% | 3,364,472 |
Delayed Quote Nyse, May 10, 2024 at 04:00 pm EDT
More quotes
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkinâs lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.3
USD
Average target price
10
USD
Spread / Average Target
+132.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +159.04% | 414M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ADCT Stock